GlaxoSmithKline, the UK's largest drug maker, tricked and bribed doctors into prescribing children with dangerous antidepressants, it was revealed last night.
The company will pay $3bn (£1.9bn) to settle a slew of charges in the United States after admitting a multi-year criminal scheme to hide unhelpful scientific evidence, manipulate articles in medical journals and lavish gifts on sympathetic doctors.
The drug at the centre of the scheme, the blockbuster pill Paxil, which is branded Seroxat in Britain, has since been banned for use by children because it can make them suicidal.
Company managers, all the way up to GSK's chief executive, Sir Andrew Witty, will have their pay and bonuses clawed back if there is any further wrongdoing, under the terms of a wide-ranging settlement with the Department of Justice. GSK admitted illegally marketing several of its drugs for uses that had not been approved by safety regulators and documents released by the Justice Department detailed the luxurious conferences in exotic climes where paid-for scientific speakers hyped up the conclusions of dubious academic papers.
GSK held eight "Paxil forum" events in Puerto Rico, Hawaii and California, where hundreds of doctors were treated to snorkelling, horse-riding, sailing, deep-sea fishing, balloon rides and spa treatments, and given an "honorarium" of $750 in cash. The company knew it was worth paying for these kinds of boondoggles; it monitored the doctors who attended and found they significantly increased prescriptions of Paxil in the months after the event.
Paxil, once GSK's best-selling drug, was never approved for use by children but because doctors were free to use their discretion, the company had a strong incentive to steer the medical profession to scientific studies that suggested it might be helpful to under-18s diagnosed with depression. Those studies were paid for by GSK itself. Sales reps for Paxil even called on paediatricians to highlight the studies.
The settlement – $1bn in criminal fines, $2bn in civil penalties – also resolved claims that GSK billed government-run healthcare plans too much for many drugs.
"Whilst these originate in a different era for the company, they cannot and will not be ignored," Sir Andrew said. "On behalf of GSK, I want to express our regret."
Glaxo will submit to a "corporate integrity agreement" with the US
government that involves a shake-up of its remuneration plan for senior managers and executives, and reflects changes already made to sales practices.
The company pleaded guilty to criminal charges related to the marketing of Paxil for use by children between 1999 and 2003, when it failed to reveal the existence of two scientific studies that showed the drug: was ineffective in treating childhood depression; cut out important caveats to the conclusion of a third study that suggested it may improve a small number of symptoms in children; over-hyped the conclusions of that study, after it was published, in marketing materials at conferences and distributed it to doctors.
GSK also illegally promoted Wellbutrin, another antidepressant, for the treatment of adult impotence, obesity and attention deficit, according to its guilty plea yesterday.Reuse content